EB 110 - Eluminex Biosciences
Alternative Names: EB-110; EB-110 - Eluminex BiosciencesLatest Information Update: 16 Jun 2023
At a glance
- Originator Eluminex Biosciences
- Class Antibodies; Eye disorder therapies
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Wet age-related macular degeneration
Most Recent Events
- 16 Jun 2023 EB 110 - Eluminex Biosciences is available for licensing as of 06 Mar 2023. https://eluminexbio.com/partnering/ (Eluminex Biosciences pipeline, March 2023)
- 06 Mar 2023 Preclinical trials in Wet age-related macular degeneration in China (Intravitreous) (Eluminex Biosciences pipeline, March 2023)
- 26 Oct 2021 Eluminex Biosciences files for patent protection for inhibitors of angiogenic factors worldwide